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ABSTRACT: Sacral neuromodulation (SNM) therapy is an 
established third line therapeutic option for the treatment of 
urgency urinary incontinence, urgency-frequency and chronic 
non-obstructive urinary retention. The continuous stimulation of 
the sacral root S3 with an electrode connected to an implanted 
pulse generator (IPG) may influence detrusor and sphincter 
activity and improve lower urinary tract symptoms. The 
mechanism of action is not completely understood and seems 
to be based on the modulation of spinal cord reflexes and brain 
centers involved in lower urinary tract function. It is implanted 
with a minimally invasive technique that can be performed 
under local anesthesia and includes a test phase that precedes the 
definitive implantation of the pulse generator. When compared to 
the standard pharmacological therapy, neuromodulation promoted 
better results both in the partial improvement of overactive bladder 
(OAB) symptoms and total continence. Moreover, sexual function, 
quality of life and depressive symptoms may also improve 
in patients with OAB that undergo SNM. However, SNM is 
associated with significant rates of adverse events and need for 
surgical revisions, requiring continuous medical attention.
Keywords: Electric stimulation therapy/adverse effects; Urinary 
bladder, overactive; Urinary incontinence; Urinary tract/
physiopathology.
RESUMO: A neuromodulação sacral (NMS) é uma opção bem 
estabelecida de tratamento de terceira linha da bexiga hiperativa, 
incluindo as indicações de urgência-frequência, incontinência 
urinária de urgência e também a retenção urinária crônica não 
obstrutiva. A estimulação contínua da raiz sacral S3, através de 
um eletrodo conectado a um gerador de pulsos implantado, pode 
influenciar a função do detrusor e do esfíncter uretral e melhorar 
os sintomas do trato urinário inferior. O mecanismo de ação não 
é totalmente conhecido e parece basear-se na modulação dos 
reflexos medulares e dos centros cerebrais envolvidos no controle 
da função do trato urinário inferior. O eletrodo sacral é implantado 
com técnica minimamente invasiva, que pode ser realizada com 
anestesia local, e inclui uma fase de teste que precede o implante 
definitivo do gerador de pulsos. Em comparação com o tratamento 
farmacológico padrão da bexiga hiperativa, a NMS promove 
melhores resultados na melhora dos sintomas e nas taxas de cura. 
Além disso, a função sexual, a qualidade de vida e os sintomas 
depressivos também podem melhorar nos pacientes com bexiga 
hiperativa que são submetidos à NMS. No entanto, a NMS 
acompanha-se de significativas taxas de eventos adversos e de 
necessidade de revisões cirúrgicas, requerendo acompanhamento 
clínico periódico. 
Descritores: Terpaia por estimulação elétrica/efeitos adversos; 
Bexiga urinária hiperativa; Incontinência urinária; Sistema 
urinário/fisiopatologia.
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INTRODUCTION
Sacral neuromodulation (SNM) was developed in the early 1980s by Tanagho and Schmidt1,2. They 
showed that continuous stimulation of the sacral root S3 
with an electrode connected to an implanted pulse generator 
(IPG) could influence detrusor and sphincter activity 
and improve lower urinary tract symptoms3. InterStim® 
Therapy (Medtronic, Minneapolis, MN, USA) is licensed 
by the US Food and Drug Administration (FDA) for the 
treatment of urinary urge incontinence (UI) since 1997 and 
for urgency-frequency (UF) and chronic non-obstructive 
urinary retention (UR) since 1999. SNM may also be used 
for other forms of bladder dysfunction including disorders 
such as chronic pelvic pain and interstitial cystitis as well 
as for faecal incontinence4-7. 
The main indication for SNM is as a third line 
therapy for overactive bladder (OAB). The International 
Continence Society (ICS) defines OAB as a syndrome 
composed of urgency, with or without urge incontinence, 
usually with frequency and nocturia8. The first line therapy 
of OAB includes behavioral treatments (BT) which are a 
group of therapies that aim to improve OAB symptoms 
by modifying patient behavior or his/her environment 
(9). Most BT programs include multiple components and 
are individualized to the needs of the patient and his/her 
particular living situation. There are two main approaches 
to BT for OAB. One targets the modification of bladder 
function by changing voiding habits, such as with bladder 
training and delayed voiding. The other approach focuses 
on the bladder outlet and includes pelvic floor muscle 
training to enhance strength and control and techniques 
for urge suppression. The second-line treatment of OAB 
consists of pharmacotherapy with antimuscarinics or a 
beta-3 agonist9. Other agents may also be used. 
When patients are refractory to conservative 
treatments (BT and pharmacotherapy) minimally invasive 
therapies such as SNM, injection of botulinum toxin in the 
detrusor or percutaneous tibial nerve stimulation may be 
indicated9. In this manuscript, we will discuss the use of 
SNM as a third line therapy for OAB. 
DISCUSSION
Mechanism of Action and Technique 
The mechanism of action of SNM is not fully 
known. The therapeutic effects of SNM may come from 
the electrical stimulation on afferent and efferent nerve 
fibers connecting the pelvic viscera and pelvic floor muscles 
and the spinal interneurons to the central nervous system. 
There is no definitive evidence of permanent remodeling, 
reinnervation or alteration of pathways in the central or 
peripheral nervous systems in humans following SNM 
therapy. It seems to predominantly affect sacral afferents 
and modulate spinal cord reflexes and brain centers that are 
involved in lower urinary tract function10-12.
The current SNM technique is minimally invasive 
and can be performed under local anesthesia. Briefly, it is 
performed with the patient in prone position using local 
anesthesia with or without mild sedation or even general 
anesthesia. Usually, a local anesthetic is applied around the 
area where the definitive lead will be implanted (posterior 
to the sacrum). With the patient awake it is possible to 
evaluate the sensory responses to electrical stimulation. 
The needle is inserted through the third sacral foramina, 
(S3). Fluoroscopy is used to monitor the position of the 
needle and the motor and sensory responses to electrical 
stimulation are tested to ascertain the adequate positioning. 
Once this is secured, a guide wire is inserted through the 
needle and serve as a guide for the dilator. Fluoroscopy is 
used to guide the appropriate positioning of the definitive 
quadripolar lead (Figure 1). After lead placement. the 
patient undergoes a test phase which may last up to 20 days, 
to determine whether SNM has provided a relevant benefit. 
It is usually accepted that improvements of more than 50% 
in symptoms are considered a successful outcome. If the 
results of the test phase are positive, the IPG is implanted 
in the upper buttocks13-15. 
 
Figure 1 - Radiographic view of 
the correct position of the electrode. 
Anterior view (left); lateral view (right)
Data: Personal archive.
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The test phase of SNM may also be performed by 
peripheral nerve evaluation (PNE), but most physicians 
prefer the staged implantation of a tined-lead for the first 
stage because the PNE technique is associated with high 
false negative rates16-18. Once implanted and in continuous 
use, the battery of the IPG has an average durability of 3 
to 6 years, depending on the parameters of stimulation 
that are used. 
SNM vs no therapy 
Outcomes of sacral nerve stimulation (SNS) for UI 
and UF are based principally on a limited number of studies 
that randomized patients to active or delayed therapy as 
well as various prospective and retrospective case series. 
Schmidt et al.19 reported on SNS therapy in 76 patients 
with refractory UI from 16 centers worldwide randomized 
to active or delayed therapy (control group) during the 
study period of 6 months19. The episodes of incontinence 
and the number of pads used were significantly reduced 
in the stimulation group when compared to the control 
group. Sixteen (47%) of the 34 patients, receiving active 
SNS therapy, were reported as completely dry and an 
additional 10 (29%) described more than 50% reduction 
in incontinence episodes. Patients returned to baseline 
levels of incontinence when stimulation was turned off. 
Hassouna et al.20 noted the outcomes of SNS for refractory 
UF in 51 patients randomized from 12 centers during an 
initial 6-month period that was extended to 2 years. The 
data report at 6 months in the active SNS group showed 
decrease in the number of daily voids (16.9 ± 9.7 to 9.3 ± 
5.1), increase in the volume voided (118 ± 74 mL to 226 
± 124 mL), lower degree of urgency (rank score of 2.2 ± 
0.6 to 1.6 ± 0.9), and improvement on the SF-36 quality 
of life (QOL) measures. At 6 months after implantation, 
stimulators in the active group were switched off and 
urinary complaints returned to baseline values. After 
reactivation of SNS, sustained efficacy was documented 
at 12 and 24 months20.
A review on the Cochrane database, from 200921, 
investigated the evidence of the effects of SNM in the 
management of UI, UF and UR. Eight RCTs were included 
in the analysis. At 6 months follow-up, SNM was superior 
to no treatment for all indications with highly significant 
improvements in all outcomes measured (leakage episodes, 
number of voids, rating of urgency, pad usage, bladder 
capacity). The authors concluded that SNM can deliver 
benefit to a selected group of patients.
SNM vs medical therapy
The InSite trial is a prospective, multi-center, 
randomized clinical trial comparing SNM to standard 
medical therapy (SMT). It is based on treating patients 
with refractory mild to moderate symptoms of OAB, 
within a six-month follow-up period18. The second phase 
is a prospective long-term evaluation of the efficacy and 
safety of SNM, to assess the cumulative five-year rate of 
adverse events (AEs) including need for surgery, rates of 
infection and lead migration as well as therapeutic success 
and QOL. Investigators have published results for one22 and 
three years15 of follow-up. The OAB therapeutic success, 
which was determined by voiding diaries at the 6-month 
follow-up visit, was defined for patients with UI and UF 
as a ≥ 50% improvement in average leaks/day or voids/day 
from baseline or a return to normal voiding frequency (<8 
voids/day), respectively. The impact on sexual function and 
depressive symptoms were additional objectives. Of 147 
randomized individuals, 93% were women and mean age 
was 58 years. Subjects randomized to SNM underwent a 
staged procedure using the InterStim during a 14-day test 
stimulation period. If a successful test stimulation occurred, 
the neurostimulator was implanted. Of the 70 subjects 
randomized to SNM, 59 underwent test stimulation and 
51/59 (86%) received a full system implant. The OAB 
therapeutic success, on the primary analysis, was greater in 
the SNM group (61%), when compared to the SMT group 
(42%; P = 0.02). 
In the final analysis, the therapy success rate was 
76% for SNM and 49% for SMT (P = 0.002). Complete 
continence was higher in the SNM group (39% vs 21% in 
the SMT group; P=0.06) which also showed significant 
improvements in QOL versus the SMT group (all P < 
0.001). The women treated with SNM had a greater 
improvement in sexual function and depression compared 
to SMT. The device-related adverse event rate was 30.5% 
and the medication-related adverse event rate was 27.3%, 
none of which were serious. The most common device-
related adverse events in SNM subjects were undesirable 
change in stimulation in 10.2% (6/59), implant site pain 
8.5% (5/59), lead migration/ dislodgment 3.4% (2/59), 
and implant site infection 3.4% (2/59). For the 51 SNM 
subjects with full system implant, the surgical intervention 
rate after 6 months was 3.9% (2/51). The most usual OAB 
medication-related events were constipation in 9.1%, drug 
toxicity in 6.5% and dry mouth in 5.2%.
SNM vs botulinum toxin-A (BTX-A)
Botulinum toxin-A (BTX-A) is approved for use as 
a third-line therapy in patients with refractory idiopathic 
OAB. The efficacy rates reported for BTX-A and SNM in 
patients with refractory OAB appear to be comparable, 
but there is no RCT to compare the efficacy and safety of 
both methods. SNM is more invasive but offers long-term 
efficacy whereas the injection of BTX-A is less invasive 
but needs to be repeated on a less than a year basis in order 
to provide sustained efficacy. Each treatment modality has 
its own range of possible AEs. 
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The ROSETTA — Refractory Overactive Bladder: 
Sacral Neuromodulation vs Botulinum Toxin Assessment 
— trial is a randomized controlled trial designed to 
compare treatment with 200U of onabotulinumtoxinA (the 
only BTX-A presentation approved for use in the bladder 
at the time of the study) injected in the detrusor versus 
SNM in female patients with refractory OAB23. A total 
of 369 patients were treated after being randomized for 
both groups. The mean age of the patients was 63 years 
and more than 80% considered themselves as severely 
or very severely incontinent. In the SNM group, subjects 
underwent a two-stage procedure. The rate of clinical 
response, measured at 1 month in the injection group and 
during the test phase in the neuromodulation group, was 
similar in the injection and SNM groups (83% vs 84%).
The onabotulinumtoxinA group reported 
significantly greater reduction in daily urgency urinary 
incontinence episodes compared to the neuromodulation 
group, concerning both the intention to treat and clinical 
responder. In the intention-to-treat analysis at 6 months, the 
change in the mean number of daily incontinence episodes 
from baseline was –3.9 in the injection group and –3.3 
episodes/day in the SNM group; P = 0.01). The injection 
group patients had greater complete symptom resolution 
at 6 months than the SNM group (20% vs 4%; P < .0001). 
Both groups had a better performance in the OAB symptom 
questionnaire. Treatment satisfaction rate was higher in 
the injection group than in the neuromodulation group 
(P = 0.01).
Adverse Events: At 6 months, the rate of urinary 
tract infection was higher in the injection group than in 
the neuromodulation group (35% vs 11%; P < .0001). 
Intermittent catheterization was required by 8% of patients 
at 1 month, 4% at 3 months, and 2% at 6 months, in the 
injection group. In the neuromodulation group, 3% of 
patients required surgical revision or removal. In this study 
a 200 U dose of onabotulinum toxin A was used, despite 
the fact that the FDA-approved dose is 100 U. Longer term 
follow-up underway may improve our understanding of 
how these treatment modalities differ in the management 
of refractory OAB. 
In another study, Smits et al.24 evaluated the use of 
SNM in patients who discontinued BTX-A treatment. They 
reported on a group of 14 patients who had discontinued 
BTX-A treatment due to lack of efficacy (85%) or the desire 
for a more permanent treatment (15%). After one year of 
implantation, 11 of 14 patients (79%) were satisfied with 
treatment24.
SNM long term data 
The long-term results of SNM have been approached 
by several case studies. It is relevant to point out that most 
studies reporting on long term data refer to older SNM 
technology and it is possible that, in the face of the new 
techniques available, efficacy and complication rates will 
improve. De Groen et al.25 evaluated the long-term results 
of SNM in patients with refractory UI. A total of 60 subjects 
were prospectively evaluated at regular intervals for at least 
5 years after implantation. Approximately 15% of patients 
achieved complete continence. After a 10-year follow-up, 
25 (61%) of 41 patients were still on active SNM.
The success rates after 10 years did not show 
much difference from the 5-year results suggesting that 
a deterioration of the results is observed during the first 
5 years, which stabilized thereafter. Fifty-seven AEs 
occurred in 32 (53%) patients, hardware failure and pain 
or discomfort at various sites were the responsibles for 
the greater number of them. Twenty-three reoperations, 
including 2 explantations, were done in 15 patients (25%). 
At 5 years post-surgery, greater than 50% 
improvement was achieved by 68% of those with UI and 
56% of those with UF, according to the evaluation of 
the same groups of OAB patients by different long-term 
studies. A number of retrospective studies stated on the long 
term efficacy of SNM for different urological conditions. A 
total of 217 patients, with a follow-up of 47 months, were 
evaluated by Peeters et al.26 The rates of success and cure 
for UI were 70% and 20%, and for UF were 68% and 33%, 
respectively. The mean time to failure after implantation, 
on the cases of unsuccessful outcome, was 24.6 months. 
Most of the re-interventions (47%) were performed within 
the first two years of follow up, At least one re-intervention 
was needed in 88 (41%) patients
The authors of the InSite study, previously quoted, 
evaluated the success rates of SNM at 1222 and 36 months15. 
Of 272 patients with the IPG, 91% were female with a mean 
age of 57 years. The final data analysis showed a sustainable 
response of SNM through 36 months, with a mean 
decrement of 2.2 leaks/day after 12 months and 2.3 leaks/
day after 36 months (P < 0.0001). Subjects demonstrated 
significant augmentation from baseline in all measures 
of ICIQ-OABqol and 80% reported improved changes in 
their urinary symptom interference at 12 and 36 months. 
Adverse effects related to the device occurred in 
16% of subjects during test stimulation, 30% of subjects 12 
months post-implant and 47% after 36 months. Undesirable 
change in stimulation (18%), implant site pain (13%), 
and therapeutic product ineffective (6%) were the most 
frequent AE types reported. Lead migrations were reported 
in 4% of subjects, most of them occurring between 12 
and 24 months post-implant. implant site infections were 
reported in 4% of individuals, half reported in the first 3 
months post-implant. Surgical interventions related to the 
neurostimulator, lead, or chronic extension ocurred in 32% 
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of subjects after implant. The replacement and revision 
rates of the device were 20% and 4%, respectively. Surgical 
interventions to perform battery replacement occurred in 
11% of subjects, and 93% of these neurostimulators were 
assessed to be within the expected longevity ranges based 
on the set parameters of the device. The top reason for 
permanent explant, which occurred in 13% of subjects, was 
due to an AE (8%). Other reasons were lack and/or loss 
of efficacy in 3%, subjects need for magnetic resonance 
imaging and “other”.
Although the long-term clinical effectiveness of 
SNM has been confirmed by many studies, its repercussion 
on patient satisfaction and enhancement of QOL has 
not been clearly stablished. One can not neglect that a 
significant proportion of patients experience technical 
problems and adverse effects requiring constant medical 
attention and surgical revisions. Leong et al.27 examined the 
patients rates of long-term satisfaction with an implanted 
SNM for various medical indications such as overactive 
bladder syndrome, non-obstructive UR, combined OAB 
and UR, and pelvic pain. Overall, 275 patients answered a 
postal questionnaire regarding satisfaction and experiences 
with the method, such as side effects, complications, 
burden, impact on sexuality and defecation changes. The 
rate of symptom improvement was 75% (207 patients) with 
a median post-implantation evaluation period of 77 months 
(range 12 to 214). The patient satisfaction rate was 90% and 
significantly related to the sensed clinical effect and 85% of 
all explanted cases (13 patients) were considered as failures. 
Satisfaction with the treatment was not associated with 
patient age, gender, duration of therapy or type of complaint 
for which SNM was offered, but was lower in patients 
with more than 1 pelvic floor comorbidity. The patient’s 
attitude towards yearly follow-up and the skill to use the 
programmer was positively related to the satisfaction rate. 
Forty percent of subjects reported some limitations or 
preoccupation with SNM such as exclusion from MRI and 
passing through metal detectors. The majority of patients 
perceived regular pain (56%) and discomfort (40%).
Table 1 shows the results for some of the most 
important studies on SNM for the treatment of refractory 
OAB. 
Predictors of outcomes
Several research groups have investigated a 
number of possible predictors of success for SNM in 
OAB patients, including age, severity of incontinence, 
obesity, prior medication use, previous spinal surgery, 
urodynamic findings and other. Davis et al showed similar 
success rates at the trial phase for patients who received 
SNS as a treatment due to lack of medication efficacy 
versus intolerable medication side effects (70% and 71% 
respectively)28. 
Yazdany et al.29 also reported the success in the test 
phase in a group of patients with severe incontinence (mean 
10.4 episodes/day); the authors observed that patients with 
>10 incontinence episodes per day had greater propensity 
to have a successful stage I trial in comparison to those 
with less than 5 episodes/day. Levin et al.30 reported on 
the influence of obesity on stage I success rates. Eighty 
(53.7%), of 149 patients, were obese (BMI mean 37.3) 
and 69 (46.3%) were non-obese (BMI mean 25.6). The 
success rates are comparable among the groups of obese 
(78%) and non-obese (83%) patients. The overall rate of 
success is 81%30.
Peters et al.31 analyzed medical records of adults 
enrolled in a prospective observational study in order 
to evaluate the impact of age on the outcomes of SNM. 
The rate of IPG implant (89-90%) and explant (9.3-13%) 
did not vary between different age groups (<40 years, 
40-64 and >/=65) but there was a tendency for higher 
complication rates in younger patients (23% vs. 15% vs. 
8.5%, respectively; P= 0.08). The same group evaluated 
possible predictors of reoperation after SNM in a single 
center retrospective study32. The data of 407 patients were 
reviewed, at least one reoperation was performed in 134 
(33%) subjects, over a median follow-up of 28.9 months, 
including 78/407 (19%) revisions and 56/407 (14%) 
explantations. The lack and/or loss of efficacy was the most 
common reason for reoperation (65%). On multivariate 
analysis, only longer follow-up (P = 0.0011; OR 1.048; 
CI 1.019, 1.078) and having a complication (P < 0.0001; 
OR 23.2; CI 11.47, 46.75) were significant predictors of 
reoperations.
Angioli et al.33 revealed their results of SNM in 
patients older than 65 years (mean patient age 76 years). 
At 12 months post-implant, 83.3% of patients reported 
improvement and 55.5% of patients reported complete 
success with ending of UUI episodes. On the same report, 
the mean episodes of UUI had a critical reduction from 6.3/
day to 0.5/day. Incontinence episodes, frequency, nocturia, 
and number of pads used daily also significantly decreased. 
All subscales of the OAB-q were significantly improved.
The role of urodynamics as an outcome predictor 
for SNM is not clear34. There was no relationship between 
the presence or absence of DO and the likelihood for 
test stimulation success, when evaluating 104 patients 
with refractory UI35. Drossaerts et al.36, while exploring 
the predictive role of conventional and ambulatory 
urodynamics for SNM outcome, found similar success rates 
for SNM in patients with storage dysfunction according to 
either conventional-UDS or ambulatory-UDS.
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Table 1. Results from selected studies on SNM for refractory overactive bladder
Author N Study design Follow up Results Adverse events
Schmidt et 
al.19
76 (34 SNM Vs. 
42 crontrol group)
randomized, 
multi-center 6 mths
16 (47%) completely dry; 10 
(29%) > 50% reduction in 
incontinence episodes
15.9% IPG site pain, 19.1%  
implant site pain, 7% lead 
migration, 32.5% surgical review
Hassouna et 
al.20
51 SNM (90% 
women)
randomized, 
multi-center 6 mths 
Daily voids from  16.9 to 9.3; 
Volume voided from  118 ml to 
226 ml; lower degree of urgency 
There were no reports of serious 
adverse events or permanent 
injury associated with the 
devices
Cochrane 
review. 21 500
Systematic 
review of 8 
randomized 
controlled 
trials
6 mths
SNM  promoted significant 
improvements compared to 
no treatment in all outcomes  
(leakage episodes, number of 
voids, rating of urgency, pad 
usage, bladder capacity)
15.3% pain at implant site, 9% 
new pain, 8.4% lead migration, 
6.1% infection, 5.5% transient 
sensation of electrical shock, 
5.4% pain at lead site, 33.3% 
surgical review
Siegel et al. 
(InSite trial)18
70 to SNM; 59 
first stage; 51 
(86%) implanted;  
77 
pharmacotherapy; 
93% women
prospective, 
multi-center, 
randomized 
6 mths
 ≥  50% improvement  in 
76% for SNM and 49% for 
pharmacotherapy (p=0.002) 
Complete continence 39% SNM 
vs 21% 
30.5% had device-related 
adverse events and 27.3% had 
medication-related AE
Noblett (inSite 
trial)22
272 subjects 
received SNM 
(91% women)
prospective, 
multi-center
12 
mths
decreased 2.2 leaks/day (P < 
0.0001), UF subjects had a 
mean reduction of 5.1 voids/
day in 12mths; 80% reported 
improved Qol
16% (56/340) had AE related 
to the device during test phase; 
30% (82/272) post implant
Siegel et al. 
(inSite trial)15
272 subjects 
received SNM 
(91% women)
prospective, 
multi-center
36 
mths
decreased 2.3 leaks/day (P< 
0.0001) and UF subjects had a 
mean reduction of 5.3  voids/
day (P <0 .0001) in 36mths; 80% 
reported improved Qol
47% (127/272) had AE related to 
the device after 36mths
Amundsen et 
al. (Rosetta 
trial)23
369 randomized  
for SNM or 
BTX-A 
randomized 
controlled, 
multi-center
6 mths
complete symptom resolution 
in 20% BTX-A vs 4% SNM. 
Reduction of at least 75% 
in episodes per day in 46% 
in Btx-A vs 26% in SNM 
(P=0.002)
UTI 35% in BTX-A group vs 
11% in SNM; CIC in 2% in 
BTX-A (P<0.001); 3% of SNM 
required surgical revision or 
removal
De Groen et 
al.25 60 women prospective 5 yrs
Success rate decreased from 
52 patients (87%) at 1 month 
to 37 (62%) at 5 years. 15% 
with complete continence; 
improvement in 68% with UI 
and 56% with UF
57 AE in 32 (53%) patients 
- hardware failure and pain or 
discomfort 
- reoperations (15 - 25%) 
- explantations (2.5% )
Peeters et al.26 217patients retrospective 47mths
70% success rate and 20% cured 
for UI; 68% success rate and 
33% cured for UF 
at least one reintervention was 
needed in 88 (41%) patients
Legends. SNM: Sacral neuromodulation; AE: adverse events; QoL: quality of life; BTX-A: botulinum toxin A (OnabotulinumtoxinA); CIC: clean 
intermittent catheterization; UI: OAB with urinary incontinence; UF: OAB without urinary incontinence; IPG: Implantable pulse generator.
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Magnetic Resonance Imaging (MRI) recommendations
There is limited evidence that MRI may be 
performed with no harm to the patient based on few case 
reports or small case series that have reported on the use of 
MRI under very specific conditions37-39. Thus, possessing 
an implantable electrical stimulation device is considered 
a contraindication to undergo an MRI.
Pregnancy
Electrical stimulation has the potential to induce 
teratogenicity or abortion and SNM has been considered 
contraindicated in pregnant women. It is advisable for the 
pregnant woman to turn off their devices until the child 
is born39. 
CONCLUSIONS
SNM is an effective therapy for selected individuals 
with UF/UI refractory to conservative therapy. Patients 
should be counseled regarding the potential for significant 
adverse events and rates of surgical revisions. Maintenance 
of favorable therapeutic effect requires patient’s 
commitment to comply with long term monitoring and 
adjustment of the implant. Preoperative predictors of 
optimal patient response to this invasive therapy remain 
unclear and the test phase is needed in almost all patients 
to ascertain the indication of the definitive implantation. 
The role of SNM in combination with other therapies is 
undefined. Continuous improvements of SNM technology 
are expected to minimize the rates of adverse events and 
surgical revision, make it MRI compatible and improve the 
durability of the therapy.
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